Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis
DOI 10.1001/archderm.141.1.31
Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005;141:31-38. (Pubitemid 40144437)
Relapse, rebound, and psoriasis adverse events: An advisory group report
DOI 10.1016/j.jaad.2005.10.029, PII S0190962205033165
Carey W, Glazer S, Gottlieb AB, et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol. 2006; 54: S171-181. (Pubitemid 43238300)
Managing moderate-to-severe psoriasis with efalizumab: Experience at a single Spanish institute
DOI 10.1111/j.1365-2133.2007.07766.x
Ferrandiz C, Carrascosa JM. Managing moderate-to-severe psoriasis with efalizumab: Experience at a single Spanish institute. Br J Dermatol. 2007; 156 (suppl. 2): 24-29. (Pubitemid 46434871)
Efalizumab in the treatment of chronic plaque psoriasis: Experiences from the largest psoriasis treatment centre in Denmark
DOI 10.1111/j.1365-2133.2007.07763.x
Kragballe K. Efalizumab in the treatment of chronic plaque psoriasis: experiences from the largest psoriasis treatment centre in Denmark. Br J Dermatol. 2007; 156 (Suppl2):7-11. (Pubitemid 46434868)
Combining traditional agents and biologics for the treatment of psoriasis
DOI 10.1016/j.sder.2005.01.002
Cather JC, Menter A. Combining traditional agents and biologics for the treatment of psoriasis. Semin Cutan Med Surg. 2005; 24:37-45. (Pubitemid 40410097)
Effective management of a psoriatic flare with narrowband UVB phototherapy during efalizumab therapy without discontinuing treatment [5]
DOI 10.1111/j.1468-3083.2006.01970.x
Carrascosa JM, Soria X, Ferrandiz C. Effective management of a psoriatic flare with narrowband UVB phototherapy during efalizumab therapy without discontinuing treatment. J Eur Acad Dermatol Venereol. 2007; 21(6):828-829. (Pubitemid 46939062)
CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: Results from a phase III international randomized, placebo-controlled trial
DOI 10.1111/j.1365-2133.2006.07344.x
Dubertret L, Sterry W, Bos JD, et al. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol. 2006; 155:170-181. (Pubitemid 43876411)
